LowGrade

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in October 2023 Conference call and webcast today at…

It's a good news, bad news story. Patients whose brain tumors have a mutated enzyme called IDH1 typically live longer than those without the mutation. But even as these tumors are initially less aggressive, they always come back. A key…

The transition of a low-grade, slow growing brain tumor to a lethal one can be delayed if neurosurgeons remove as much as possible soon after diagnosis, according to the results of a study led by UC San Francisco. The findings run counter…

…

PTI New Delhi, November 27The Indian Council of Medical Research has issued guidelines warning against the use of antibiotics for conditions such as…

Credit: Journal of Power Sources (2022). DOI: 10.1016/j.jpowsour.2022.231339 Thermally regenerative ammonia batteries can produce electricity…

Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib Topline results from the full FIREFLY-1 trial population expected in Q1 2023…

By CARLA K. JOHNSON - AP Medical Writer A cancer diagnosis is scary. Some doctors say it’s time to rename low-grade prostate cancer to eliminate the alarming C-word.Cancer cells develop in nearly all…

A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for the treatment of…

Drugs developed to treat AIDS and HIV could offer hope to patients diagnosed with the most common form of primary brain tumour. The breakthrough, co-funded by the charity Brain Tumour Research, is significant because, if further research is…